The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
about
Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus TherapyA Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C VirusVirologic Tools for HCV Drug Resistance TestingStructures of hepatitis C virus nonstructural proteins required for replicase assembly and functionREdiii: a pipeline for automated structure solution.Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisionsMolecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of ResistanceSubstrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug ResistanceStructural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172Hepatitis C in Argentina: epidemiology and treatment.Small molecule inhibitors of HCV replication from pomegranateHepatitis C virus NS3 mutations in haemophiliacsCoronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistanceA system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutationsStructural analysis of asunaprevir resistance in HCV NS3/4A proteaseClinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/RibavirinAccounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.Prediction of resistance development against drug combinations by collateral responses to component drugs.Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceInterdependence of Inhibitor Recognition in HIV-1 Protease.Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionHepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Improving Viral Protease Inhibitors to Counter Drug Resistance.Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization.Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided DesignNew horizons in hepatitis C antiviral therapy with direct-acting antivirals.The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.New treatments for chronic hepatitis C: an overview for paediatricians.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.ForceGen 3D structure and conformer generation: from small lead-like molecules to macrocyclic drugs.Guidelines for the successful generation of protein-ligand complex crystals.Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.
P2860
Q26700073-2430C05E-C9C2-4CEC-95AE-B18C29575117Q26700115-4F40E535-4F40-4D0C-B0D9-DF238846EC98Q26774374-857F3F5F-555B-4532-B783-884364FDE6C1Q26991855-8EB97877-FC23-4C91-BA42-CE52A61BCC58Q27317992-BB1DC89E-E8D0-4E59-837A-516FB4A7952BQ27468990-6527731D-75E4-4AF2-BDA4-80AE2A2CADBCQ27675615-8E58E187-A630-4A17-A723-562A0E7FC32EQ27679880-FCFD8D31-69BE-4D7D-B91B-AB6667CAFE5BQ27703170-E2702CD0-2D1B-4CFC-BA37-2451E1B170D1Q33706886-F05B84F5-4F14-4F7E-8B49-6A3039BD3C71Q33794802-0B7BA46F-34F2-4441-884E-33B23279EA64Q34111759-6EF361F7-582E-4FA8-B047-27F9115B990AQ34261616-4797772F-95E2-424F-9E0C-AEF45EAA49F4Q34430652-1FB45AD6-3677-4804-BF0D-5B46D232C34BQ34576194-AF9CBAD6-E7F0-4DD5-9657-1104B2551228Q34802167-809D6892-0785-434A-8EA5-4F387A3D4187Q35092054-D8716748-CD34-4454-B029-FE9B5237A896Q35854877-BC600C51-8FC7-4E83-B84C-5EA1AEF7D7E1Q36096436-B2C372ED-1C0D-4489-B70E-0AC69173341FQ36290778-E0BD4F26-AD7C-41C3-9FC8-F877D8E511F4Q36327966-A810AED1-8426-4357-8D44-043584B698E2Q36505470-17882705-9790-4F3E-9731-5C6ECD59929BQ36933403-F8AB21F8-D959-4C8D-9C02-CA7E0CBF2F68Q37017282-8FA916A7-7925-4379-9A95-A336771C30BEQ37176685-4A45C273-5507-458D-804B-0454EF29E049Q37446341-8794BADB-A45E-460A-AE4E-C1DDDBF53B5DQ37604079-391FA7D6-F296-4265-A7E9-E5EA7C9FA226Q38087250-41A749BA-D3F8-4C34-93D2-8A96472E32D8Q38113079-F2CE1088-EFD7-4EC3-87EE-32A3EA281F4FQ38180719-44B69BB6-D14A-4568-B1E3-1221C4C5CD4EQ38282842-533A9A88-E712-47D3-B891-E61E0A0340BAQ38533619-165DE44D-2A0D-4005-96E8-419C17FFEC08Q38715350-D5BE577E-40D4-472C-8B49-E65B2E8D772EQ38771000-A0AC4158-5DF0-48F2-AD2D-A4CF06191801Q38826176-1EC4C2AA-D4CE-41CB-9EE0-48BBF11B20ACQ38893104-2AA50BF4-7164-4663-A8D1-8A5E7CE93780Q38909972-408FF09D-EFD4-4856-A7C2-35B70BAF064CQ38972442-A5522678-6D1C-430C-B906-CA7C19E6EEBAQ39500905-4F09BC3E-EB72-4701-8FB2-910CD9619266Q40167650-4286E009-FD22-42EF-8DCA-5D5EA9DF807D
P2860
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@ast
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@en
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@nl
type
label
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@ast
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@en
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@nl
altLabel
The molecular basis of drug re ...... rus NS3/4A protease inhibitors
@en
prefLabel
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@ast
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@en
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@nl
P2093
P2860
P3181
P1433
P1476
The Molecular Basis of Drug Re ...... rus NS3/4A Protease Inhibitors
@en
P2093
Alicia Newton
Ayşegül Ozen
Casey Silver
Celia A Schiffer
Christos J Petropoulos
Djade Soumana
Keith P Romano
Laura M Deveau
P2860
P304
P3181
P356
10.1371/JOURNAL.PPAT.1002832
P407
P50
P577
2012-01-01T00:00:00Z